Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a 'Buy' rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintained a price target of $60.
August 10, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rocket Pharmaceuticals has received a reiterated 'Buy' rating from Needham analyst Gil Blum, with a maintained price target of $60.
The reiterated 'Buy' rating and maintained price target by Needham analyst Gil Blum indicates a positive outlook for Rocket Pharmaceuticals. This could potentially lead to increased investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100